New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
NCT ID NCT04550494
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 47 times
Summary
This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study includes up to 36 participants with various cancers (breast, prostate, ovarian, pancreatic, gastric) and aims to see if the drug can shrink tumors or slow their growth, and whether taking different PARP inhibitors one after another might be beneficial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
-
National Institutes of Health Clinical Center
ACTIVE_NOT_RECRUITINGBethesda, Maryland, 20892, United States
-
UF Health Cancer Institute - Gainesville
RECRUITINGGainesville, Florida, 32610, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talazoparib (a PARP inhibitor)
What this could lead to
If successful, this trial could show that talazoparib helps shrink or control advanced cancers with specific DNA repair defects, and may guide sequential use of different PARP inhibitors.
What could go wrong
This is a small, early-phase (phase 2) study with only 36 participants. It focuses on biological markers rather than direct survival benefits, so results may not translate to widespread clinical use. Side effects of talazoparib include fatigue, nausea, and low blood counts.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.